2017 American Transplant Congress
Anti-CD40 mAb Promotes Kidney Immunoregulatory Capacity in NHP Transplants by Altering Kidney Tubular Cell (TEC) Expression of CD40 and IL-6.
Treatment of cynolmolgus monkey (NHP) renal transplant recipients with a combination of 2 rhesus-mouse chimeric α-CD45RB (r6G3R1; 6G3) and α-CD40 (r2C10R4; 2C10) mAbs increased circulating…2017 American Transplant Congress
Steroid Withdrawal and De Novo Donor-Specific HLA Antibodies in Renal Transplant Patients: A Prospective, Randomized, Controlled Study in Parallel Groups. Preliminary Results.
Introduction: Steroids represent a mainstay of immunosuppression after kidney transplant (KT). Steroid withdrawal reduces metabolic and cardiovascular complications, but whether it increases the risk of…2017 American Transplant Congress
Alemtuzumab Induction Is Associated with a Lower Incidence of BK Virus Nephropathy Compared with IL2RA Induction.
Renal Medicine, West London Renal and Transplant Centre, London, United Kingdom
Introduction:BK polyoma virus associated nephropathy [BKVAN] is a major cause of allograft dysfunction and graft loss occurring in up to 10% of kidney allograft recipients…2017 American Transplant Congress
Trends in Infection Among Kidney Transplant Recipients, 1999-2013.
Johns Hopkins School of Medicine, Baltimore, MD
Modern immunosuppression regimens have substantially reduced acute rejection and improved patient and graft survival over the last decades. However, such potent regimens may also have…2017 American Transplant Congress
Variability in Tacrolimus Concentrations Across Pediatric Solid Organ Transplants.
PURPOSE: We characterized the evolution of out-of-range tacrolimus (TAC) concentrations and associated factors during 1 year following a pediatric solid organ transplant (SOT).METHODS: Heart, kidney…2017 American Transplant Congress
Early and Late High Intrapatient Variability of Tacrolimus Levels Can Predict Late Renal Allograft Rejection.
Introduction Nonadherence to immunosuppressive medication can start any time after transplantation and is associated with rejection and graft loss. We have previously shown that high…2017 American Transplant Congress
Conversion from Tacrolimus-Based to Everolimus-Based Immunosuppressive Therapy 3 Months After Living-Donor Kidney Transplantation: A Randomized-Controlled Clinical Trial.
While conversion from ciclosporin to everolimus is well documented, conversion from tacrolimus has been poorly studied. In this randomized-controlled trial the safety and tolerability of…2017 American Transplant Congress
A Novel, Dose-Adjusted Tacrolimus Trough Concentration (TTC) Model for Prediction and Variance Estimation.
Given that a high tacrolimus (tac) intrapatient variability (IPV) increases the risk for a poor kidney transplant (tx) outcome, some experts advocate routine IPV monitoring…2017 American Transplant Congress
Evolution of CCR4highCD4+ Subpopulations in Renal Graft Blood After Steroid Withdrawal: A Prospective, Randomized, Controlled Study in Parallel Groups. Preliminary Results.
Introduction:Steroids are a mainstay of immunosuppression after kidney transplant (KT). The infiltration into the graft of active T cells following KT depends on the expression…2017 American Transplant Congress
This is Why We Can't Have Nice Things- Real World Experience with Everolimus in Livers.
Purpose: To determine if discontinuation rates of everolimus (RAD) in clinical practice is higher than the 30% demonstrated in trials.Methods: This was a retrospective cohort…
- « Previous Page
- 1
- …
- 99
- 100
- 101
- 102
- 103
- …
- 138
- Next Page »